October 8, 2011

Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study

.   .   

The ASCERTAIN study was a randomized controlled trial comparing three strategies: replacement of calcineurin inhibitor (CnI) with everolimus; addition of everolimus and CnI reduction; or CnI minimization. There was no difference in renal function, acute rejection rates or graft loss at 2 years. Of note, the mean time post-transplant of patients in this trial was greater than five years, which suggests that any benefit that mTOR inhibitors may provide require their initiation relatively early post-transplant.

Related Articles:

Renal Transplantation

Comments are closed.